Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H28O5 |
| Molecular Weight | 360.4448 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(=O)CO)[C@]1(C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C)C=O
InChI
InChIKey=PQSUYGKTWSAVDQ-ZVIOFETBSA-N
InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
| Molecular Formula | C21H28O5 |
| Molecular Weight | 360.4448 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Aldosterone is a hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Recent findings have shown that the physiological functions of the hormone aldosterone go far beyond its well-known role in blood-pressure regulation and salt/water homeostasis. Aldosterone is for example involved in the regulation of inflammation, and also binds directly to mineralocorticoid receptors in specific brain regions. At the late distal tubule and collecting duct, aldosterone has two main actions: 1) aldosterone acts on mineralocorticoid receptors (MR) on principal cells in the distal tubule of the kidney nephron, increasing the permeability of their apical (luminal) membrane to potassium and sodium and activates their basolateral Na+/K+ pumps, stimulating ATP hydrolysis leading to phosphorylation of the pump and a conformational change in the pump exposes the Na+ ions to the outside. The phosphorylated form of the pump has a low affinity for Na+ ions, hence reabsorbing sodium (Na+) ions and water into the blood, and secreting potassium (K+) ions into the urine; 2) aldosterone stimulates H+ secretion by intercalated cells in the collecting duct, regulating plasma bicarbonate (HCO3−) levels and its acid/base balance; and 3) aldosterone may act on the central nervous system via the posterior pituitary gland to release vasopressin (ADH) which serves to conserve water by direct actions on renal tubular resorption.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21375792 | https://www.ncbi.nlm.nih.gov/pubmed/18377905
Curator's Comment: Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder in rodent models.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26907965 |
3.8 nM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
83.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13769961/ |
ALDOSTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
||
83% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13769961/ |
ALDOSTERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
||
60% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13769961/ |
ALDOSTERONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3 mg single, intravenous Highest studied dose Dose: 3 mg Route: intravenous Route: single Dose: 3 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
6 mg 3 times / day multiple, intramuscular Highest studied dose Dose: 6 mg, 3 times / day Route: intramuscular Route: multiple Dose: 6 mg, 3 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolic alkalosis. | 2001-04 |
|
| Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. | 2001-04 |
|
| Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland. | 2001-04 |
|
| Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. | 2001-04 |
|
| Local inhibition of nitric oxide temporarily stimulates aldosterone secretion in conscious sheep in vivo. | 2001-04 |
|
| Serious adverse events experienced by patients with chronic heart failure taking spironolactone. | 2001-04 |
|
| The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. | 2001-04 |
|
| Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. | 2001-04 |
|
| Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. | 2001-04 |
|
| Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. | 2001-04 |
|
| Diagnosis and management of congenital adrenal hyperplasia: clinical, molecular and prenatal aspects. | 2001-03-13 |
|
| Effect of therapeutic ultrasound on partition and diffusion coefficients in human stratum corneum. | 2001-03-12 |
|
| Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities. | 2001-03 |
|
| Nesiritide for the treatment of decompensated heart failure. | 2001-03 |
|
| Effect of chronic oral administration of a low dose of captopril on sodium appetite of hypothyroid rats. Influence of aldosterone treatment. | 2001-03 |
|
| Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001-03 |
|
| Modulation of transalveolar fluid absorption by endogenous aldosterone in adult rats. | 2001-03 |
|
| Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. | 2001-03 |
|
| Adverse cardiac effects of salt with fludrocortisone in hypertension. | 2001-03 |
|
| Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. | 2001-03 |
|
| Water metabolism disturbances at different stages of primary thyroid failure. | 2001-03 |
|
| Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers. | 2001-03 |
|
| A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. | 2001-03 |
|
| Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. | 2001-03 |
|
| Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. | 2001-03 |
|
| Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. | 2001-03 |
|
| Type 1 aldosterone synthase deficiency presenting in a middle-aged man. | 2001-03 |
|
| Approach to the patient with hypertension, unexplained hypokalemia, and metabolic alkalosis. | 2001-03 |
|
| Salt intake and body fluid volumes: have we learned all there is to know? | 2001-03 |
|
| Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations. | 2001-03 |
|
| Inhibition of aldosterone production in rat adrenal mitochondria by 18-ethynyl-11-deoxycorticosterone: a simple model for kinetic interpretation of mechanism-based inhibitors. | 2001-03 |
|
| The release of antidiuretic hormone is appropriate in response to hypovolemia and/or sodium administration in children with severe head injury: a trial of lactated Ringer's solution versus hypertonic saline. | 2001-03 |
|
| Non-genomic actions of aldosterone: role in hypertension. | 2001-03 |
|
| Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation. | 2001-02-28 |
|
| Molecular mechanisms of human hypertension. | 2001-02-23 |
|
| Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture. | 2001-02-15 |
|
| [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]. | 2001-02-03 |
|
| Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study. | 2001-02 |
|
| Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids. | 2001-02 |
|
| K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. | 2001-02 |
|
| Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. | 2001-02 |
|
| Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. | 2001-02 |
|
| Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. | 2001-02 |
|
| C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. | 2001-02 |
|
| Workshop: mechanisms and cardiovascular damage in hypertension. | 2001-02 |
|
| Effect of furosemide on renal excretion of oxypurinol and purine bases. | 2001-02 |
|
| Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. | 2001-02 |
|
| Renal function, sodium and water homeostasis in patients with idiopathic extrahepatic portal vein thrombosis compared with normal healthy controls. | 2001-01 |
|
| Tackling polycystic ovary syndrome. | 2001-01 |
|
| Preformulation experiences and in vitro model studies with spironolactone-containing suppositories. | 2001-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11744652
Horses: Aldosterone was injected intravenously for 6 h at 20-min intervals (total 5.4 ug/kg body wt).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29180329
Curator's Comment: Cultured neonatal rat ventricular cardiomyocytes were stimulated in vitro with 1 umol/L aldosterone for 24 h. Aldosterone modulates the expression of cardiac voltage-operated Ca2+ channels and accelerates beating in cultured neonatal rat ventricular myocytes. v
Aldosterone within the concentration range of 0.01-1.0 umol/L stimulates the proliferation and osteogenic gene expressions and enhances α-ENaC gene expression in rat osteoblasts in vitro, suggesting the possibility that ENaC participates in aldosterone-mediated regulation of osteoblast functions.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:01 GMT 2025
by
admin
on
Mon Mar 31 17:50:01 GMT 2025
|
| Record UNII |
4964P6T9RB
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
92896-0
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
34231-1
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
NCI_THESAURUS |
C2324
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
1765-7
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
13482-5
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
30894-0
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
35185-8
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
1762-4
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
25845-9
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
WHO-ATC |
H02AA01
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
1764-0
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
31992-1
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
41023-3
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
14587-0
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
92897-8
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
35186-6
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
15010-2
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
1763-2
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
CFR |
21 CFR 862.1045
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
WHO-VATC |
QH02AA01
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
14586-2
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
||
|
LOINC |
44295-4
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
52-39-1
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
DTXSID7022419
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
4964P6T9RB
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
SUB05306MIG
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
5839
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
100000087869
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
C219
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
6251-69-0
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
ALTERNATIVE | |||
|
4964P6T9RB
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL273453
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
m1488
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
30834
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
111
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
73856
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
27584
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
D000450
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
ALDOSTERONE
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
DB04630
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
483
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
200-139-9
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | |||
|
1312358
Created by
admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
A clear hierarchy of antinatriuretic activity, aldosterone > 5.alpha.-DHA > 3.alpha.,5.alpha-THA > 3.alpha.,5.beta.-THA > 3.beta.,5.alpha.-THA > 5.beta.-DHA > 3.beta.,5.beta.-THA was observed
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
A clear hierarchy of antinatriuretic activity, aldosterone > 5.alpha.-DHA > 3.alpha.,5.alpha-THA > 3.alpha.,5.beta.-THA > 3.beta.,5.alpha.-THA > 5.beta.-DHA > 3.beta.,5.beta.-THA was observed
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||